X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (322) 322
female (219) 219
androstadienes - therapeutic use (210) 210
fluticasone (208) 208
male (183) 183
index medicus (174) 174
androstadienes - administration & dosage (157) 157
asthma - drug therapy (146) 146
middle aged (144) 144
adult (142) 142
androstadienes - economics (135) 135
albuterol - analogs & derivatives (123) 123
asthma (110) 110
treatment outcome (109) 109
drug combinations (104) 104
aged (102) 102
adolescent (90) 90
albuterol - therapeutic use (90) 90
administration, inhalation (87) 87
fluticasone propionate (86) 86
cost-benefit analysis (82) 82
salmeterol (75) 75
respiratory system (74) 74
anti-asthmatic agents - therapeutic use (72) 72
bronchodilator agents - therapeutic use (71) 71
salmeterol xinafoate (71) 71
albuterol - economics (70) 70
albuterol - administration & dosage (69) 69
child (68) 68
asthma - economics (67) 67
bronchodilator agents - administration & dosage (67) 67
drug therapy, combination (67) 67
androstadienes - adverse effects (62) 62
pulmonary disease, chronic obstructive - drug therapy (61) 61
inhaled corticosteroids (60) 60
pharmacology & pharmacy (60) 60
retrospective studies (59) 59
double-blind method (58) 58
anti-asthmatic agents - economics (56) 56
corticosteroids (56) 56
fluticasone-salmeterol drug combination (55) 55
allergy (54) 54
drug therapy (50) 50
anti-asthmatic agents - administration & dosage (45) 45
bronchodilator agents - economics (45) 45
efficacy (42) 42
immunology (39) 39
budesonide (38) 38
medicine & public health (38) 38
medicine, general & internal (38) 38
care and treatment (35) 35
copd (35) 35
double-blind (35) 35
quality of life (35) 35
breast neoplasms - drug therapy (34) 34
budesonide - therapeutic use (34) 34
children (34) 34
therapy (34) 34
anti-inflammatory agents - therapeutic use (33) 33
formoterol fumarate (33) 33
quality-of-life (33) 33
young adult (33) 33
analysis (32) 32
androstadienes - pharmacology (32) 32
formoterol (32) 32
breast cancer (31) 31
cardiac & cardiovascular systems (31) 31
chronic obstructive pulmonary disease (31) 31
cohort studies (31) 31
drug costs (31) 31
aged, 80 and over (30) 30
asthma - physiopathology (30) 30
dose-response relationship, drug (30) 30
ethanolamines - administration & dosage (30) 30
drug administration schedule (29) 29
exacerbations (29) 29
persistent asthma (29) 29
pulmonary and respiratory medicine (29) 29
randomized controlled trials as topic (29) 29
administration, intranasal (28) 28
budesonide - administration & dosage (28) 28
child, preschool (28) 28
research (28) 28
adrenal cortex hormones - therapeutic use (27) 27
animals (27) 27
pulmonary disease, chronic obstructive - economics (27) 27
glucocorticoids - therapeutic use (26) 26
management (26) 26
montelukast (26) 26
propionate (26) 26
rhinitis, allergic, seasonal - drug therapy (26) 26
acetates - therapeutic use (25) 25
cost-effectiveness (25) 25
internal medicine (25) 25
lung diseases, obstructive (25) 25
mortality (25) 25
quinolines - therapeutic use (25) 25
steroids (25) 25
time factors (25) 25
adults (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 2012, Volume 7, pp. 221 - 233
Purpose: To investigate equivalency of results from multivariable regression (MR) and propensity score matching (PSM) models, observational research methods... 
Statistical bias | Pulmonary disease | Propensity score | Statistical models | Chronic obstructive | Multivariate analysis | Outcomes research | ISSUES | TRIALS | statistical bias | pulmonary disease | RESPIRATORY SYSTEM | statistical models | EXACERBATIONS | chronic obstructive | outcomes research | multivariate analysis | propensity score | Androstadienes - economics | Bronchodilator Agents - therapeutic use | Drug Costs | Multivariate Analysis | Ambulatory Care - utilization | Muscarinic Antagonists - economics | United States | Humans | Middle Aged | Male | Models, Economic | Muscarinic Antagonists - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Adrenal Cortex Hormones - economics | Ipratropium - therapeutic use | Anti-Bacterial Agents - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Retrospective Studies | Albuterol - economics | Drug Therapy, Combination | Emergency Service, Hospital - utilization | Odds Ratio | Pulmonary Disease, Chronic Obstructive - economics | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Anti-Bacterial Agents - economics | Bronchodilator Agents - economics | Albuterol - analogs & derivatives | Linear Models | Logistic Models | Treatment Outcome | Models, Statistical | Scopolamine Derivatives - economics | Propensity Score | Emergency Service, Hospital - economics | Adrenergic beta-2 Receptor Agonists - economics | Cost-Benefit Analysis | Ipratropium - economics | Albuterol - therapeutic use | Aged | Ambulatory Care - economics | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Drug Combinations | Hospitalization - economics | Pulmonary Disease, Chronic Obstructive - drug therapy | Economic aspects | Lung diseases, Obstructive | Care and treatment | Research | Patient outcomes | Medical care, Cost of | Methodology
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 2004, Volume 20, Issue 2, pp. 225 - 240
SUMMARY Background: Current asthma guidelines recommend that patients are educated to adjust their medication according to their asthma severity using... 
Salmeterol/fluticasone | Exacerbations | Asthma control | Budesonide/formoterol | Adjustable maintenance dosing | Fixed dosing | ASTHMA CONTROL | EXACERBATIONS | BUDESONIDE/FORMOTEROL | FIXED DOSING | ADJUSTABLE MAINTENANCE DOSING | SALMETEROL/FLUTICASONE | GUIDED SELF-MANAGEMENT | MEDICINE, RESEARCH & EXPERIMENTAL | adjustable maintenance dosing | salmeterol/fluticasone | BUDESONIDE | asthma control | SYMPTOMS | SALMETEROL | FORMOTEROL | MEDICINE, GENERAL & INTERNAL | fixed dosing | exacerbations | TRADITIONAL TREATMENT | budesonide/formoterol | Androstadienes - economics | Drug Costs | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Fluticasone | Ethanolamines - administration & dosage | Budesonide - economics | Albuterol - administration & dosage | Aged, 80 and over | Adult | Female | Albuterol - economics | Bronchodilator Agents - adverse effects | Child | Bronchodilator Agents - economics | Salmeterol Xinafoate | Double-Blind Method | Drug Administration Schedule | Pulmonary Ventilation - drug effects | Albuterol - analogs & derivatives | Ethanolamines - economics | Asthma - drug therapy | Androstadienes - administration & dosage | Analysis of Variance | Budesonide - adverse effects | Adolescent | Aged | Budesonide - administration & dosage | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Albuterol/administration & dosage/adverse effects/analogs & derivatives/economics | Asthma/drug therapy | Pulmonary Ventilation/drug effects | Budesonide/administration & dosage/adverse effects/economics | Bronchodilator Agents/administration & dosage/adverse effects/economics | Ethanolamines/administration & dosage/adverse effects/economics | Aged; 80 and over | Androstadienes/administration & dosage/adverse effects/economics
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 12, pp. 1786 - 1793
Summary Background Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-dose combination of indacaterol (IND), a long-acting β2 -adrenergic... 
Pulmonary/Respiratory | Costs | Cost-minimisation | Cost-effectiveness | Economic evaluation | COPD | MORTALITY | GOLD | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | GUIDELINES | COMBINATION | SALMETEROL | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | Androstadienes - economics | Bronchodilator Agents - therapeutic use | Quinolones - economics | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Fluticasone | Indans - economics | Indans - therapeutic use | Sweden | Drug Costs - statistics & numerical data | Quinolones - therapeutic use | Female | Indans - administration & dosage | Albuterol - economics | Drug Therapy, Combination | Pulmonary Disease, Chronic Obstructive - economics | Bronchodilator Agents - economics | Salmeterol Xinafoate | Glycopyrrolate - economics | Double-Blind Method | Glycopyrrolate - therapeutic use | Albuterol - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Cost-Benefit Analysis | Albuterol - therapeutic use | Aged | Androstadienes - therapeutic use | Monte Carlo Method | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Family medicine | Health care industry | Lung diseases, Obstructive | Glycine | Studies | Pneumonia | Mortality | Population | Chronic obstructive pulmonary disease | Drug therapy | Patients | Drug dosages | Monte Carlo simulation | Cost control | Clinical Medicine | Lungmedicin och allergi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Respiratory Medicine and Allergy
Journal Article
International Journal of COPD, ISSN 1176-9106, 2011, Volume 6, Issue 1, pp. 13 - 22
Purpose: Relative costs and utilization-related outcomes of a fluticasone propionate 250 mu g + salmeterol 50 mu g combination (FSC), tiotropium bromide, and... 
Tiotropium | Costs | Chronic obstructive pulmonary disease | Ipratropium | Utilization | Advair | costs | RESPIRATORY SYSTEM | ipratropium | utilization | Advair (R) | chronic obstructive pulmonary disease | tiotropium | Androstadienes - economics | Drug Costs | Hospital Costs | Glucocorticoids - therapeutic use | United States | Cholinergic Antagonists - economics | Humans | Middle Aged | Emergency Medical Services - economics | Male | Models, Economic | Ipratropium - therapeutic use | Drug Prescriptions - economics | Time Factors | Glucocorticoids - economics | Female | Retrospective Studies | Albuterol - economics | Pulmonary Disease, Chronic Obstructive - economics | Scopolamine Derivatives - therapeutic use | Cholinergic Antagonists - therapeutic use | Insurance, Pharmaceutical Services - economics | Tiotropium Bromide | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Albuterol - analogs & derivatives | Treatment Outcome | Scopolamine Derivatives - economics | Cost-Benefit Analysis | Ipratropium - economics | Albuterol - therapeutic use | Aged | Ambulatory Care - economics | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Drug Combinations | Hospitalization - economics | Pulmonary Disease, Chronic Obstructive - drug therapy | Indexing in process | Original Research
Journal Article
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 9/2017, Volume 34, Issue 9, pp. 2163 - 2172
Chronic obstructive pulmonary disease is associated with a high healthcare resource and cost burden. Healthcare resource utilization was analyzed in patients... 
Cost analyses | Trial-based healthcare resource utilization | Single inhaler triple therapy | Rheumatology | Fluticasone furoate/umeclidinium/vilanterol | Internal Medicine | Oncology | Randomized controlled trials | COPD burden | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | Budesonide/formoterol | Endocrinology | MORTALITY | MEDICINE, RESEARCH & EXPERIMENTAL | INHALED CORTICOSTEROIDS | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | EXACERBATIONS | TIOTROPIUM | PHARMACOLOGY & PHARMACY | COHORT | Androstadienes - economics | Bronchodilator Agents - therapeutic use | Formoterol Fumarate - therapeutic use | Bronchodilator Agents - economics | Double-Blind Method | Humans | Middle Aged | Male | United Kingdom | Adrenal Cortex Hormones - therapeutic use | Adrenal Cortex Hormones - economics | Budesonide - economics | Formoterol Fumarate - economics | Nebulizers and Vaporizers - economics | Budesonide - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Androstadienes - therapeutic use | Pulmonary Disease, Chronic Obstructive - economics | Pulmonary Disease, Chronic Obstructive - drug therapy | Medical research | Lung diseases, Obstructive | Utilization | Analysis | Medicine, Experimental | Medical care | Health care industry | Medical care, Cost of | Budesonide | Original Research | umeclidinium | Fluticasone furoate | vilanterol | formoterol
Journal Article
Respiratory Medicine, ISSN 0954-6111, 08/2017, Volume 129, pp. 199 - 206
Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment... 
Fixed-dose combination inhalers | Formoterol | GINA | Cost-effectiveness | Real-life | Asthma | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | EFFICACY | OPEN-LABEL | BUDESONIDE/FORMOTEROL | SALMETEROL | ASTHMA CONTROL | THERAPY | RESPIRATORY SYSTEM | DISEASE | INSIGHTS | Androstadienes - economics | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Ethanolamines - administration & dosage | Asthma - economics | Adult | Female | Cost-Benefit Analysis - economics | Anti-Asthmatic Agents - economics | Treatment Outcome | Ethanolamines - economics | Patient Acceptance of Health Care - statistics & numerical data | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Fluticasone-Salmeterol Drug Combination - economics | Quality of Life | Ethanolamines - therapeutic use | Aged | Androstadienes - therapeutic use | United Kingdom - epidemiology | Drug Combinations | Cohort Studies | Evaluation | Analysis | Pharmacy | Salmeterol | Drugstores | Dosage and administration | Research institutes | Drug therapy, Combination | Steroids | Medical care, Cost of | Health care | Therapy | Costs | Health services | Propionic acid | Fluticasone | Patients | Data bases | Impact analysis | Quality of life | Confidence intervals | Studies | Databases | Chronic obstructive pulmonary disease | Cost analysis | Drug therapy | Drug dosages | Cost engineering
Journal Article
Respiratory Research, ISSN 1465-9921, 02/2012, Volume 13, Issue 1, pp. 15 - 15
Background: This retrospective cohort study compared the risks of exacerbations and COPD-related healthcare costs between patients with chronic obstructive... 
Exacerbation | Pharmacoeconomics | Pharmacotherapy | Chronic obstructive pulmonary disease | Hospitalization | Emergency room visit | Cost | Triple therapy | Add-on therapy | emergency room visit | cost | LONG-ACTING BETA-AGONISTS | hospitalization | EFFICACY | COPD EXACERBATIONS | RANDOMIZED-TRIAL | exacerbation | SALMETEROL | add-on therapy | PROPIONATE | triple therapy | ECONOMIC-ASSESSMENT | RESPIRATORY SYSTEM | pharmacotherapy | pharmacoeconomics | CORTICOSTEROIDS | 50 MU-G | chronic obstructive pulmonary disease | Androstadienes - economics | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - economics | Humans | Middle Aged | Albuterol - analogs & derivatives | Male | Risk | Treatment Outcome | Drug Therapy, Combination - economics | Scopolamine Derivatives - economics | Disease Progression | Albuterol - therapeutic use | Female | Aged | Androstadienes - therapeutic use | Retrospective Studies | Albuterol - economics | Fluticasone-Salmeterol Drug Combination | Pulmonary Disease, Chronic Obstructive - economics | Scopolamine Derivatives - therapeutic use | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Tiotropium | Lung diseases, Obstructive | Patient outcomes | Salmeterol | Dosage and administration | Research | Fluticasone | Drug therapy | Economic aspects | Drugstores | Corticosteroids | Pharmacy | Lung diseases | Medical care, Cost of | Health insurance | Health Insurance Portability & Accountability Act 1996-US | Costs | Health care policy | Emergency medical care | Manuscripts | Generalized linear models | Quality of life
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 106, Issue 6, pp. 829 - 837
Summary Objective To determine clinical and economic outcomes following COPD-related hospitalization/emergency department (ED) care in patients receiving COPD... 
Pulmonary/Respiratory | Economics | Pharmacotherapy | Chronic obstructive pulmonary disease | Hospitalization | Utilization | CARDIAC & CARDIOVASCULAR SYSTEMS | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | COMBINATION THERAPY | ADMINISTRATIVE DATA | INHALED CORTICOSTEROIDS | CLINICAL COMORBIDITY INDEX | SALMETEROL | OBSTRUCTIVE PULMONARY-DISEASE | MEDICAID PATIENTS | RESPIRATORY SYSTEM | EXACERBATIONS | QUALITY-OF-LIFE | Androstadienes - economics | Bronchodilator Agents - therapeutic use | United States - epidemiology | Glucocorticoids - therapeutic use | Cholinergic Antagonists - economics | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - epidemiology | Ipratropium - therapeutic use | Patient Selection | Drug Costs - statistics & numerical data | Glucocorticoids - economics | Adult | Female | Retrospective Studies | Albuterol - economics | Pulmonary Disease, Chronic Obstructive - economics | Scopolamine Derivatives - therapeutic use | Cholinergic Antagonists - therapeutic use | Tiotropium Bromide | Bronchodilator Agents - economics | Albuterol - analogs & derivatives | Treatment Outcome | Scopolamine Derivatives - economics | Health Care Costs - statistics & numerical data | Ipratropium - economics | Albuterol - therapeutic use | Aged | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Patient Readmission - statistics & numerical data | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Corticosteroids | Lung diseases | Patient outcomes | Emergency medicine | Fluticasone | Drug therapy | Prescription drugs | Airway management | Health Insurance Portability & Accountability Act 1996-US | Hospitals | Sensitivity analysis | Antibiotics | Mortality | Data bases | Manuscripts | Cost control
Journal Article
Journal Article